Kamada Ltd. (KMDA)

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth

Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth

CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders

Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026

Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"

KMDA or PRTA: Which Is the Better Value Stock Right Now?

Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Bet

Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript

Kamada (KMDA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates

Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance

Kamada Announces Planned Transition of Chief Financial Officer

Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026

Reviewing InflaRx (NASDAQ:IFRX) and Kamada (NASDAQ:KMDA)

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting